By modulating the TIME and immune checkpoint pathways, acetylation significantly impacts immunotherapy efficacy, particularly through regulating PD-L1 expression, immune cell infiltration, and tumor cell survival, positioning it as a promising target for therapeutic innovation [79]. This evidence concerns the gene CD274 and neoplasm.